Sana Pharma proudly announces the release of two new medications in the Jordanian market. Vorasan, Vortioxetine, the first and only antidepressant that improves cognitive function associated with daily functioning at work, home and socially, and it has been found to be the most effective and best-tolerated option for major depressive disorder (MDD).

Molnovir, Molnupiravir, the first oral, FDA-Approved, direct acting anti viral drug for the treatment of mild to moderate covid-19 disease.